Analysts forecast that PhaseBio Pharmaceuticals Inc (NASDAQ:PHAS) will post $400,000.00 in sales for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for PhaseBio Pharmaceuticals’ earnings. The lowest sales estimate is $240,000.00 and the highest is $550,000.00. PhaseBio Pharmaceuticals reported sales of $260,000.00 during the same quarter last year, which would suggest […]
